Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Primate cell – per se
Patent
1997-12-04
2000-05-02
Degen, Nancy
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Primate cell, per se
435 6, 4353201, 435325, 536 231, 536 245, C12Q 168, C12N 1585, C12N 1563, C07H 2104
Patent
active
06057156&
ABSTRACT:
Enzymatic nucleic acid molecules which cleave EGFR RNA.
REFERENCES:
patent: 4987071 (1991-01-01), Cech et al.
patent: 5334711 (1994-08-01), Sproat et al.
patent: 5525468 (1996-06-01), McSwiggen
Aurup et al., "Chapter 10: Stabilized RNA Analogs for Antisense and Ribozyme Applications," Delivery Strategies for Antisense Oligonucleotide Therapeutics, 161-177 (1995).
Ayers et al., "Polyacrylic acid mediated ocular delivery of ribozymes," Journal of Controlled Release, 38:167-175 (1996).
Bacchetti et al., "Telomerers and Telomerase in Human Cancer (Review)," International Journal of Oncology 7:423-432 (1995).
Barinaga, "Ribozymes: Killing the Messenger," Science, 262:1512-1514 (1993).
Bassi et al., "Ionic interactions and the global conformations of the hammerhead ribozyme," Nature Structural Biol., 2(1):45-55 (1995).
Beck, et al, (1996).
Beck, et al., (1997).
Beigelman et al., "Alternate Approaches to the Synthesis of 2'-O-Me Nucleosides," Nucleosides and Nucleotides, 14(3-5):421-425 (1995).
Beigelman et al., "Chemical Modification of Hammerhead Ribozynes," Journal of Biological Chemistry, 270(43):25702-25708 (1995).
Beigelman et al., "Synthesis of 1-Deoxy-D-Ribofuranose Phosphoramidite & the Incorporation of Abasic Nucleotides in Stem-Loop II of A Hammerhead Ribozyme," Biorg. Med. Chem. Lett. 4(14):1715-1720 (1994).
Beigelman et al., "Synthesis of 2'-modified nucleotides and their incorporation into hammerhead ribozymes," Nucleic Acids Research, 23(21):4434-4442 (1995).
Beltinger et al., "Binding, Uptake, and Intracellular Trafficking of Phosphorothioate-modified Oligodeoxynucleotides," J. Clin. Invest., 95:1814-1823 (1995).
Bertrand et al., "Anti-HIV Therapeutic Hammerhead Ribozymes: Targeting Strategies and Optimization of Intracellular Function," Nucleic Acids and Molecular Biology 10:301-313 (1996).
Bertrand et al., "Can hammerhead ribozymes be efficient tools to inactivate gene function?" Nucleic Acids Research 22(3):293-300 (1994).
Bertrand et al., "Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1," EMBO Journal, 13(12):2904-2912 (1994).
Bigner et al., "Cytogenetics and Molecular Genetics of Malignant Gliomas and Medulloblastoma," Brain Pathol., 1:12-18 (1990).
Black et al., "Brain Tumors," New England Journal of Medicine 324(21):1471-1476 & (22):1555-1564 (1991).
Blackburn et al., (1990).
Bratty et al., "The Hammerhead RNA Domain, a Model Ribozyme," Biochimica et Biophysica Acta. 1216:345-359 (1993).
Brem, et al., "Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas," Journal of Neurosurgery, 74:441-446 (1991).
Bruner, "Neuropathology of Malignant Gliomas," Seminars in Oncology, 21(2):126-138 (1994).
Cech et al., "Biological Catalysis By RNA," Annual Review of Biochemistry, 55:599-629 (1986).
Cech et al., "Hammerhead Nailed Down," Nature, 372:39-40 (1994).
Cech et al., "In Vitro Splicing of the Ribosomal RNA Precursor of Tetrahymena: Involvement of a Guanosine Nucleotide in the Excision of the Intervening Sequence," Cell, 27:487-496 (1981).
Cech, "Ribozymes and Their Medical Implications," JAMA 260(20):3030-3034 (1988).
Chadeneau et al., "Telomerase Activity in Normal and Malignant Murine Tissues," Oncogene 11:893-898 (1995).
Chen et al., "Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates," Nucleic Acids Research 20(17):4581-4589 (1992).
Chen et al., "Effects on Tumor Cells of Ribozymes that Cleave the RNA Transcripts of Human Papillomavirus Type 18," Cancer Gene Therapy 3(1):18-23 (1996).
Chowrira et al., "Extensive Phosphorothioate Substitution Yields Highly Active and Nuclease-Resistant Hairpin Ribozymes," Nucleic Acids Research 20(11):2835-2840 (1992).
Chowrira et al., "In Vitro and in Vivo Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-Processing Ribozyme Cassettes," J. Biol. Chem. 269(41):25856-25864 (1994).
Christoffersen and Marr, "Ribozymes as Human Therapeutic Agents," J. Med. Chem. 38(12):2023-2037 (1995).
Christoffersen et al., "Application of Computational Technologies to Ribozyme Biotechnology Products," Journal of Molecular Structure (Theochem) 311:273-284 (1994).
Collins et al., "Reaction Conditions and Kinetics of Self-Cleavage of a Ribozyme Derived From Neurospora VS RNA," Biochemistry 32:2795-2799 (1993).
Couture and Stinchcomb, "Anti-gene Therapy: the Use of Ribozymes to Inhibit Gene Function," TIG, 12(12):510 (1996).
Crooke, "Therapeutic Applications of Oligonucleotides," Annual Review of Pharmacology and Toxicology, 32:329-379 (1992).
Denman, "Biocomputing: Using RNAFOLD to Predict the Activity of Small Catalytic RNAs," BioTechniques, 15(6):1090-1094 (1993).
Denman, "Facilitator Oligonucleotides Increase Ribozyme RNA binding to full-length RNA Substrates in vitro," FEBS Letters 382:116-120 (1996).
Downward, "Close similarity of Epidermal Growth Factor Receptor and v-erb-B Oncogene Protein Sequences," Nature 307(5951):521-527 (1984).
Dreyfus, "Restriction Ribozymes?" Einstein Quarterly Journal of Biology and Medicine 6(2):92-93 (1988).
Dropulic et al., "Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression," Journal of Virology 66(3):1432-1441 (1992).
Dropulic et al., "Meeting Report-Ribozymes: Use as Anti-HIV Therapeutic Molecules," Antisense Research and Development, 3:87-94 (1993).
Eckstein, "Nucleoside Phoshorothioates," Annual Review of Biochemistry 54:367-402 (1985).
Ekstrand et al., "Genes for Epidermal Growth Factor Receptor, Transforming Growth Factor .alpha., and Epidermal Growth Factor and Their Expression in Human Gliomas in Vivo," Cancer Research 51:2164-2172 (1991).
Elkins et al., "Cellular Delivery of Ribozymes," Delivery Strategies for Antisense Oligonucleotide Therapeutics, London, CRC Press, 17-37 (1995).
Ellis et al., "Design and Specificity of Hammerhead Ribozymes Against Calretinin mRNA," Nucleic Acids Research 21(22):5171-5178 (1993).
Elroy-Stein et al., "Cytoplasmic Expression System Based on Constitutive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells," Proc. Natl. Acad. Sci. USA 87:6743-6747 (1990).
Fedor et al., "Kinetics of Intermolecular Cleavage by Hammerhead Ribozymes," Biochemistry 31:12042-12054 (1992).
Fedor et al., "Substrate sequence effects on "hammerhead" RNA catalytic efficiency," Proc. Natl. Acad. Sci. USA 87:1668-1672 (1990).
Feldstein et al., "Two Sequences Participating in the Autolytic Processing of Satellite Tobacco Ringspot Virus Complementary RNA," Gene 82:53-61 (1989).
Felgner et al., "Enhanced Gene Delivery and Mechanism Studies with a Novel Series of Cationic Lipid Formulations," Journal of Biological Chemistry 269(4):2550-2561 (1994).
Feng et al., "The RNA Component of Human Telomerase," Science 269:1236-1241 (1995).
Fine, et al., "Meta-Analysis of Radiation Therapy with and without Adjuvant Chemotherapy for Malignant Gliomas in Adults," Cancer, 71(8):2585-2597, (1993).
Flory et al., "Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint," Proc. Natl. Acad. Sci. USA, 93:754-758 (1996).
Forster and Altman, "External Guide Sequences for an RNA Enzyme," Science 249:783-786 (1990).
Forster et al., "Self-cleavage of Plus and Minus RNAs of a Virusoid and a Structural Model for the Active Sites," Cell 49:211-220 (1987).
Fu et al., "Importance of specific purine amino and hydroxyl groups for efficient cleavage by a hammerhead ribozyme," Proc. Natl. Acad Sci. USA, 89:3985-3989 (1992).
Gait et al., "Synthetic Ribonucleotide Analogues for RNA Structure-Function Studies," Nucleosides and Nucleotides 14(3-5):1133-1144 (1995).
Gao et al., "Ctyoplasmic Expression of a Receptor Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes," Nucleic Acids Research 21(12):2867-2872 (1993).
Gish et al., "Phosphorothioates in Molecular Biology," Trends in Bio
Akhtar Saghir
Fell Patricia
McSwiggen James A.
Degen Nancy
Robozyme Pharmaceuticals, Inc.
Wang Andrew
LandOfFree
Enzymatic nucleic acid treatment of diseases or conditions relat does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enzymatic nucleic acid treatment of diseases or conditions relat, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enzymatic nucleic acid treatment of diseases or conditions relat will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1593099